Brown Bags

SDAC: Clinical Trials Brown Bag Discussion Series

Title Date Presenter
The FDA’s Final Rule on Expedited Safety Reporting: Implications for Data Monitoring of Clinical Trials Wednesday, October 5, 2016 – 12:00pm to 1:00pm Robin Bechhofer
OSLER: An Open-Label Randomized Extension Trial of Evolocumab Wednesday, October 7, 2015 – 12:00pm Marian Fisher
Electroconvulsive Therapy for Severe Depression Wednesday, September 9, 2015 – 12:00pm Neil Baron
Conducting Valid Trials: the Critical (and Misunderstood) Roles of Randomization and Complete Follow-Up Wednesday, May 6, 2015 – 12:00pm to 1:00pm Tom Cook
— a preview of the workshop to be presented at SCT 2015
Clinical Trial Research in the Context of a Global Epidemic: Drug and Vaccine Studies for Ebola Virus Disease Wednesday, March 4, 2015 – 12:00pm to 1:00pm Robin Bechhofer
Transparency, Sharing, and Reanalysis of Clinical Trial Data: Recent Publications Wednesday, February 4, 2015 – 12:00pm to 1:00pm Melissa Schultz
Social Media and Crowdsourcing: A Consideration of Impacts on Clinical Trials and Health Research Wednesday, January 7, 2015 – 12:00pm to 1:00pm Allison Furey
A Review of Analyses for Drug Induced Liver Injury Wednesday, December 17, 2014 – 12:00pm to 1:00pm Gabriel Nicholas
STABILITY/SOLID TIMI-52 Darapladib Trials: Background, Results, and Monitoring Wednesday, November 12, 2014 – 12:00pm to 1:00pm Scott Diegel
Mindfulness Meditation as an Intervention for Chronic Low Back Pain Wednesday, October 8, 2014 – 12:00pm to 1:00pm John Kloke
Temporal Changes in Post-Discharge Risk among Patients Hospitalized for Heart Failure: An EVEREST Story Wednesday, September 3, 2014 – 12:00pm to 1:00pm Ryan Zea
Abstract: Studies have shown patients suffering from a heart failure hospitalization are at higher risk for an adverse event in the first 90 days post-discharge. This claim has led to the conclusion of a vulnerable phase for these patients. The vulnerable phase hypothesis has ties to research, health care, and quality of care initiatives. However, as the case with chronic diseases, shouldn’t risk continue to increase over time? A post-hoc analysis of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) trial, may show just that.
The Study of Platelet Inhibition and Patient Outcomes (PLATO) Trial: Criticism and Responses Wednesday, May 14, 2014 – 12:00pm to 1:00pm Brian Traver
Fish Oil: Benefits of Omega-3 Polyunsaturated Fatty Acids Wednesday, April 2, 2014 – 12:00pm to 1:00pm Neil Baron
Everolimus: A mTOR Inhibitor for Treatment of Breast Cancer Wednesday, February 5, 2014 – 12:00pm to 1:00pm Weiqun Tong
Adaptive Trials from 30,000 Feet Wednesday, January 8, 2014 – 12:00pm to 1:00pm Tom Cook
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: Context and Controversy Wednesday, December 4, 2013 – 12:00pm to 1:00pm Marian Fisher
PKCS-9 Monoclonal Antibodies for Treatment of High LDL-Cholesterol Wednesday, November 6, 2013 – 12:00pm to 1:00pm Kevin Buhr
Issues from the FDA Advisory Committee Meeting to Review the New Drug Application (NDA) for the use of Tovaptan to Treat Autosomal Dominant Polycystic Kidney Disease (ADPKD) Wednesday, October 2, 2013 – 12:00pm to 1:00pm Robin Bechhofer
Studies from the SDAC Archives: PROMISE and PRAISE Wednesday, May 1, 2013 – 12:00pm to 1:00pm Jan Feyzi
The Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF) Trial: Overview and Results Wednesday, April 3, 2013 – 12:00pm to 1:00pm Melissa Schultz
Placebo Effects Tuesday, March 19, 2013 – 12:00pm to 1:00pm Allison Furey
Recent developments in Rheumatoid Arthritis Wednesday, January 23, 2013 – 12:00pm to 1:00pm Gabriel Nicholas
Major Depressive Disorder (in Children and Adolescence), Overview of the Pristiq Phase III Pediatric Trials Wednesday, December 5, 2012 – 12:00pm to 1:00pm Scott Diegel


Additional Information

Jeanne McCabe
Clinical Trials Program Manager